APA (7th ed.) Citation

GK, A., SM, G., AB, N., F, I., Q, S., P, K., . . . AP, V. (2024). CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma. Cancer research communications, 4(3), 682. https://doi.org/10.1158/2767-9764.CRC-22-0516

Chicago Style (17th ed.) Citation

GK, Abou-Alfa, et al. "CALGB 80802 (Alliance): Impact of Sorafenib with and Without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma." Cancer Research Communications 4, no. 3 (2024): 682. https://doi.org/10.1158/2767-9764.CRC-22-0516.

MLA (9th ed.) Citation

GK, Abou-Alfa, et al. "CALGB 80802 (Alliance): Impact of Sorafenib with and Without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma." Cancer Research Communications, vol. 4, no. 3, 2024, p. 682, https://doi.org/10.1158/2767-9764.CRC-22-0516.